Celgene bets $6M on wound care biotech; Lilly partners up for Lou Gehrig's development;

@FierceBiotech: Gilead charts PhIII success for leukemia drug as J&J showdown awaits. More | Follow @FierceBiotech

@JohnCFierce: Check out my webinar Thursday morning with Toni Ribas and Carol Gallagher on targeted cancer drugs. More | Follow @JohnCFierce

@DamianFierce: AstraZeneca just can't wait to get to Cambridge, plans to deploy 400 scientists to get R&D ball rolling. Story | Follow @DamianFierce

@EmilyMFierce: As resistance rises, one MIT team is investigating how a bacteria-derived toxin could help design new antibiotics. Article | Follow @EmilyMFierce

> Celgene ($CELG) invested $6 million in wound care company Alliqua, also handing over marketing rights to two of its related products. More

> Eli Lilly ($LLY) teamed up with Project A.L.S. to develop treatments for amyotrophic lateral sclerosis, or Lou Gehrig's disease. Item

> Cardiome snatched up Swiss drugmaker Correvio in exchange for $12 million and 19.9% of its outstanding shares. News

> The FDA is approving more and more drugs each year, and the rate is unlikely to slow, according to a report. Story

Medical Device News

@FierceMedDev: Study: Medtronic next-gen pacer tech achieves atrial fibrillation delay. More | Follow @FierceMedDev

@MarkHFierce: Cardiovascular Systems wants to sell 2.1M shares in a public offering. Simply put: expansion requires funding. Story | Follow @MarkHFierce

@MichaelGFierce: Spoke to MIT's Dr. Robert Langer about drug delivery and nanotech. Story in tomorrow's FierceDrugDelivery report. | Follow @MichaelGFierce

> Congress faces pushback over proposed Medicare medical imaging cuts. Item

> Medtronic's otherwise stellar Q2 stained by spinal revenue declines. More

> NEJM: Stents don't beat drugs in treating clogged renal arteries. Article

Pharma News

@FiercePharma: Monday's most-read story: Takeda's new outsider CFO charged with $1B cost-cutting plan. More | Follow @FiercePharma

@EricPFierce: Patheon, DSM join forces in $2.6B deal, to create no name company with global reach. More | Follow @EricPFierce

@CarlyHFierce: U.S. approves drug tracking, compound pharmacy oversight law. Story from FiercePharmaManufacturing | Follow @CarlyHFierce

> One certainty: Drug spending will hit $1 trillion in 2014. Story

> EMA: No new safety flags in Roche's stash of unreported side effects. Report

> Philly jury hits J&J with $11M verdict in Topamax birth-defects case. Article

Pharma Manufacturing News

> Glaxo to use new technology in India plant. Report

> 2 Puerto Rico plants up next in Merck job-whacking plan. Story

> J&J, Merck KGaA roll out new China plant projects. Article

> DSM, Patheon join up in $2.6B deal. More

> U.S. approves drug tracking, compound pharmacy oversight law. Story

> Mylan recalls 480,000 bottles of blood pressure med. Item

Biotech Research News

> Tekmira's RNAi antivirals protect animals from lethal doses of Ebola, Marburg. More

> Oxford, MRC Technology team up on migraine drug discovery. Item

> First-ever 'mini-kidney' organs created from human stem cells. Story

> Bacteria-derived toxin could provide design for new antibiotics. Article

> Herb-based compounds improve learning, memory in Alzheimer's mice. News

> Compound that targets fat-burning mechanism discovered. Report

Suggested Articles

Plexium is launching with $28 million to build its platform and a pipeline of drugs that target the enzymes drive recognition of protein targets.

In this week's EuroBiotech Report, Healx raises $56 million, Boehringer's VC wing backs anti-cancer virus startup and Ipsen bags Blueprint drug.

In our EuroBiotech roundup this week, GammaDelta forms antibody spinout, gene therapy startup raises cash and Amsterdam plans medical business park.